https://pharminent.com/immunovants-potential-autoimmune-blockbuster-waves-rna-editing-update/ 2026-05-20T15:55:07Z Pharminent en Immunovant's potential autoimmune 'blockbuster'; Wave's RNA editing update 2026-05-20T14:43:50Z Blog https://pharminent.com/pazdur-declines-to-announce-candidacy-for-vacated-fda-commissioner-role/ 2026-05-20T15:55:27Z Pharminent en Pazdur declines to announce candidacy for vacated FDA commissioner role 2026-05-20T14:32:30Z Blog https://pharminent.com/80847-2/ 2026-05-19T23:59:48Z Pharminent en 2026-05-19T23:59:38Z Blog https://pharminent.com/oncology/oncology-intelligence-digest-may-19-2026/ 2026-05-19T23:45:57Z Pharminent en Oncology Intelligence Digest • May 19, 2026 2026-05-19T23:44:15Z Blog https://pharminent.com/strategic-news-watch/strategic-news-watch-may-19-2026/ 2026-05-19T17:31:27Z Pharminent en Strategic News Watch • May 19, 2026 2026-05-19T17:31:16Z Blog https://pharminent.com/relay-doubles-the-bar-outpacing-novartis-with-a-60-response-in-rare-disease/ 2026-05-19T16:15:20Z Pharminent en Relay doubles the bar, outpacing Novartis with a 60% response in rare disease 2026-05-19T14:50:02Z Blog https://pharminent.com/biomarin-suffers-another-blow-to-rare-disease-portfolio-in-phase-3-flop/ 2026-05-19T16:15:39Z Pharminent en BioMarin suffers another blow to rare disease portfolio in Phase 3 flop 2026-05-19T11:48:58Z Blog https://pharminent.com/ucb-reports-positive-outcomes-for-bimekizumab-in-psoriatic-arthritis/ 2026-05-19T16:15:44Z Pharminent en UCB reports positive outcomes for bimekizumab in psoriatic arthritis 2026-05-19T11:48:33Z Blog https://pharminent.com/european-study-shows-inequality-in-access-to-new-medicines/ 2026-05-19T16:15:55Z Pharminent en European study shows inequality in access to new medicines 2026-05-19T11:27:19Z Blog https://pharminent.com/sanofi-says-drug-for-rare-disease-aatd-tops-standard-care/ 2026-05-19T16:16:00Z Pharminent en Sanofi says drug for rare disease AATD tops standard care 2026-05-19T10:13:40Z Blog https://pharminent.com/scotus-wont-hear-pharmas-ira-complaints/ 2026-05-19T16:16:06Z Pharminent en SCOTUS won't hear pharma's IRA complaints 2026-05-19T09:00:16Z Blog https://pharminent.com/rare-disease-gene-therapy/rare-disease-gene-therapy-digest-may-18-2026/ 2026-05-18T23:07:09Z Pharminent en Rare Disease & Gene Therapy Digest • May 18, 2026 2026-05-18T23:06:51Z Blog https://pharminent.com/strategic-news-watch/strategic-news-watch-may-18-2026/ 2026-05-18T17:11:23Z Pharminent en Strategic News Watch • May 18, 2026 2026-05-18T17:11:13Z Blog https://pharminent.com/merck-adc-licensed-from-china-hits-mark-in-first-big-global-trial/ 2026-05-19T16:21:38Z Pharminent en Merck ADC, licensed from China, hits mark in first big global trial 2026-05-18T15:49:00Z Blog https://pharminent.com/regeneron-parabilis-set-out-to-create-new-drug-class-in-deal-worth-up-to-2-3b/ 2026-05-18T16:04:31Z Pharminent en Regeneron, Parabilis set out to create new drug class in deal worth up to $2.3B 2026-05-18T14:23:15Z Blog https://pharminent.com/hospital-prices-have-risen-much-faster-for-private-insurance-than-medicare-since-2019/ 2026-05-19T16:21:55Z Pharminent en Hospital Prices Have Risen Much Faster for Private Insurance Than Medicare Since 2019 2026-05-18T14:18:46Z Blog https://pharminent.com/astrazeneca-wins-nod-for-blood-pressure-pill-opening-new-class-of-hypertension-drugs/ 2026-05-18T16:04:51Z Pharminent en AstraZeneca wins nod for blood pressure pill, opening new class of hypertension drugs 2026-05-18T13:07:12Z Blog https://pharminent.com/novartis-reveals-more-data-behind-pluvicto-expansion-bid/ 2026-05-18T16:06:25Z Pharminent en Novartis reveals more data behind Pluvicto expansion bid 2026-05-18T12:38:48Z Blog https://pharminent.com/regeneron-immunotherapy-combo-comes-up-short-in-melanoma-trial/ 2026-05-18T16:04:54Z Pharminent en Regeneron immunotherapy combo comes up short in melanoma trial 2026-05-18T11:55:00Z Blog https://pharminent.com/japans-mhlw-approves-boehringers-jascayd-for-ipf-and-ppf/ 2026-05-18T16:06:05Z Pharminent en Japan's MHLW approves Boehringer's Jascayd for IPF and PPF 2026-05-18T10:13:15Z Blog https://pharminent.com/fda-approves-enhertu-for-two-her2-positive-early-breast-cancer-indications-2/ 2026-05-18T16:02:16Z Pharminent en FDA approves Enhertu for two HER2-positive early breast cancer indications 2026-05-18T07:49:17Z Blog